Menu
Press Release:
Read Now
NGS-Based 'Liquid Biopsy' at Wellness Visits
Can Increase Early Cancer Detection...
NGS-Based 'Liquid Biopsy' at Wellness Visits Can Increase Early Cancer Detection...
Read Now
Unleashing the Power of Genomics to Improve Pet Health
PetDx® – The Liquid Biopsy Company for Pets™ is a San Diego-based molecular diagnostics company. Its flagship product, OncoK9®, enables veterinarians to detect cancer in dogs with a simple blood draw. As a first-in-class multi-cancer early detection (MCED) test, OncoK9 employs cutting-edge genomic analysis that leverages next-generation sequencing (NGS) technology and proprietary bioinformatics algorithms, empowering veterinarians to provide superior care to canine patients.
PetDx Company Video: Discover the inspiration for PetDx® and the unique collaboration that made the vision for OncoK9® a reality.
Video production courtesy of Illumina®. All rights reserved.
Executive Team
Board of Directors
Want to join the PetDx Pack? We are hiring.
Browse our open positions and submit your application.
Clinical Advisory Board
Scientific Advisors
Commercial Advisors
Partners
Investors
Laboratory
PetDx performs high-complexity molecular diagnostic testing at its state-of-the-art ISO-certified laboratory in the Center for Novel Therapeutics at the University of California San Diego's Science Research Park.
All OncoK9 testing and interpretation steps are performed at the PetDx central laboratory in San Diego, California (ISO 9001:2015 Certificate Nr. 1807). Two state-of-the-art Illumina NovaSeq 6000 Next-Generation Sequencing instruments are used for the high-complexity testing required to generate OncoK9 results.
Join the Revolution in Early Cancer Detection for Dogs
If you are ready to add the OncoK9 multi-cancer early detection test to your veterinary practice, we would love to hear from you.